Derivative exercise or conversion — not an open-market buy.
Traded Feb 17, 2026 · Filed Feb 19, 2026
Idexx Laboratories's Executive Vice President sold $1.69M of Idexx Laboratories shares. Nobody planned it ahead of time.
Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell
open market sale
Code S — open-market or private sale
~$1,692,427
Shares × reported transaction price
15 days after results of Feb 2, 2026, 77 days before results of May 5, 2026
Results dates are the company's own 8-K (Item 2.02). Many companies only let insiders trade in a window after results
Closed at $626.17 on Feb 17, 2026, 73% above its 52-week low and 18% below its high, after a 7% drop over the previous 30 trading days
52-week range $361.04 (Apr 8, 2025) to $766.68 (Nov 25, 2025), 65% of the way up, from 251 adjusted closes. 30 trading days earlier: $669.99 on Jan 2, 2026. Describes the past only, not a forecast
None found in footnotes
Only flagged when a footnote says so; never inferred
| After | Stock | S&P 500 | Difference |
|---|---|---|---|
| 7 days | +3.3% | -0.5% | +3.8% |
| 30 days | -9.0% | -4.9% | -4.0% |
| 90 days | -13.0% | +7.7% | -20.7% |
| 180 days | -11.6% | +11.6% | -23.1% |
Past results only. Not a forecast.
Derivative exercise or conversion — not an open-market buy.
Derivative exercise or conversion — not an open-market buy.
20K → 18K shares held−9% of their stake
Idexx Laboratories's Executive Vice President sold $1.12M of Idexx Laboratories shares. Nobody planned it ahead of time.